Lupin has received Euro 20 million from patent rights
Lupin has received Euro 20 million from Laboratoires Servier of France for the sale of additional patent rights to Perindopril.
Dr. Kamal K Sharma, managing director, Lupin said, “This income significantly boosts our performance for the current year. We are very pleased with the transaction and it goes a long way to further demonstrate our IP capabilities.”
Earlier this year the company had received euro 20 million (over Rs 115 crore) from Laboratories Servier of France towards the sale of certain patent applications and other related intellectual property for the generic version of high blood pressure drug, Perindopril to multiple countries.
Sources had said that although perindopril, as a chemical entity, came off patent in June 2003, its generic versions are rare in the global markets. Perindopril, marketed as Coversyl tablets by Servier, is a new class of cardiovascular drugs such as Ramipril and Lisinopril. Servier has taken four different “process patents related to the processes used to synthesize perindopril and its key intermediates”.
Servier is the largest independent French pharmaceutical company with a turnover of over 2.8 billion euros in 2004-2005. About 73% of the company’s turnover is contributed by drugs for cardiovascular and veneous diseases. Coversyl is the lead brand which contributes about 31% of its turnover.
